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the Beneficial Impact of Pioglitazone on Progression
of Coronary Atherosclerosis in Diabetic Patients
Insights From the PERISCOPE (Pioglitazone
Effect on Regression of Intravascular Sonographic
Coronary Obstruction Prospective Evaluation) Study
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Alfonso Perez, MD,§ Richard Nesto, MD, Steven E. Nissen, MD*
Cleveland, Ohio; Deerfield, Illinois; and Burlington, Massachusetts
Objectives The purpose of this study was to determine the factors associated with the favorable effect of pioglitazone on
atheroma progression.
Background Diabetes mellitus is associated with accelerated coronary atheroma progression. Pioglitazone slowed progres-
sion compared with glimepiride in this population.
Methods In all, 360 diabetic patients with coronary artery disease were treated with pioglitazone or glimepiride for 18months in the
PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation)
study. Coronary atheroma progression was evaluated by serial intravascular ultrasound. The relationship between changes
in biochemical parameters, percent atheroma volume, and total atheroma volume was investigated.
Results Pioglitazone-treated patients demonstrated greater increases in high-density lipoprotein cholesterol (HDL-C) and re-
ductions in glycated hemoglobin, triglycerides, and C-reactive protein. Significant correlations were observed between
changes in percent atheroma volume and triglycerides (r  0.15, p  0.04), triglyceride/HDL-C ratio (r  0.16, p 
0.03), and glycated hemoglobin (r  0.16, p  0.03) with pioglitazone, and changes in low-density lipoprotein choles-
terol (r  0.15, p  0.05), apolipoprotein B (r  0.16, p  0.04), and apolipoprotein A-I (r  0.20, p  0.01)
with glimepiride. Substantial atheroma regression, compared to progression, was associated with greater relative in-
creases in HDL-C (14.2% vs. 7.8%, p  0.04), relative decreases in triglycerides (13.3% vs. 1.9%, p  0.045),
triglyceride/HDL-C ratio (22.5 vs. 9.9%, p  0.05), and decrease in glycated hemoglobin (0.6% vs. 0.3%,
p  0.01). Multivariable analysis revealed that pioglitazone-induced effects on triglyceride/HDL-C were associated
with changes in percent atheroma volume (p  0.03) and total atheroma volume (p  0.02).
Conclusions Favorable effects of pioglitazone on the triglyceride/HDL-C ratio correlated with delayed atheroma progression in diabetic
patients. This finding highlights the potential importance of targeting atherogenic dyslipidemia in diabetic patients with cor-
onary artery disease. (J Am Coll Cardiol 2011;57:153–9) © 2011 by the American College of Cardiology Foundation
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Diabetes, Lipids, and Plaque Progression January 11, 2011:153–9The presence of diabetes mellitus
portends an adverse cardiovascu-
lar prognosis in the presence and
absence of established coronary
heart disease (1–3). Despite the
relationship between hyperglyce-
mia and prospective cardiovascu-
lar risk in population studies,
glucose-lowering strategies gen-
erally have not reduced event
rates in randomized controlled
trials (4,5). This observation is
supported by recent trials that
report a lack of efficacy, and
potential harm, in trials of in-
tensive glycemic control (6 –9).
As a result, considerable debate
has focused on the need to eval-
ate the cardiovascular safety of emerging antidiabetic
herapies (10).
In contrast, therapeutic interventions that lower low-
ensity lipoprotein cholesterol (LDL-C) and blood pressure
re associated with unequivocal reductions in macrovascular
vents (11–15). As a result of these observations, guidelines
or cardiovascular prevention in patients with diabetes
ellitus emphasize the need for intensive lowering of these
isk factors (16). Increasingly, attention has focused on the
mportance of hypertriglyceridemia, low levels of high-
ensity lipoprotein cholesterol (HDL-C), and inflamma-
ion as factors driving diabetic cardiovascular disease.
Coronary artery imaging with intravascular ultrasonogra-
hy has demonstrated accelerated progression of atheroscle-
osis in patients with diabetes, despite the use of intensive
ipid-lowering regimens (17). These findings suggest that
dditional therapies will be required to achieve more effec-
ive prevention of cardiovascular events in diabetic patients.
he PERISCOPE (Pioglitazone Effect on Regression of
ntravascular Sonographic Coronary Obstruction Prospec-
ive Evaluation) study compared the impact of 2 glucose-
owering strategies, pioglitazone and glimepiride, on disease
rogression and demonstrated that the peroxisome prolif-
rator activated receptor- agonist pioglitazone halted pro-
ression of coronary atherosclerosis (18). The current anal-
sis was designed to determine the traditional biochemical
actors that were associated with this antiatherosclerotic
ctivity.
ethods
ubject selection. The details of the PERISCOPE study
ave been described in detail previously (18). In brief, 543
atients with type 2 diabetes mellitus with a diagnosis of
oronary artery disease, defined as the presence of at least 1
0% lumen stenosis in a major epicardial coronary artery on
n angiogram performed for a clinical indication were
Abbreviations
and Acronyms
Apo  apolipoprotein
CRP  C-reactive protein
EEM  external elastic
membrane
HbA1c  glycated
hemoglobin
HDL-C  high-density
lipoprotein cholesterol
LDL-C  low-density
lipoprotein cholesterol
PAV  percent atheroma
volume
TAV  total atheroma
volumenrolled in the study. Patients were treated for 18 months cith either glimepiride 1 to 4 mg or pioglitazone 15 to 45
g with dose titration to achieve a fasting plasma glucose
140 mg/dl. Coronary intravascular ultrasonography imag-
ng was performed at baseline and at the end of the study in
60 patients. The study was approved by each participating
enter’s institutional review board.
mage acquisition and analysis. The details of ultrasonic
mage acquisition and analysis have been described in detail
reviously. Briefly, after anticoagulation therapy and admin-
stration of intracoronary nitroglycerin, a high frequency (40
Hz) ultrasound transducer (Atlantis SR Pro, Boston
cientific, Maple Grove, Minnesota) was placed as distally
s possible within the target coronary artery. Imaging was
cquired while continuously withdrawing the catheter
hrough the artery back to the aorta at a constant rate of 0.5
m/s by a motorized pullback. Images were digitized, and
nalysis of each segment was selected by using proximal and
istal side branches as reference points to enable subsequent
nalysis of the same segment at follow-up. Images spaced 1
m apart were selected for analysis. The leading edges of
he lumen and external elastic membrane (EEM) were
raced by manual planimetry. Total atheroma volume
TAV) was calculated as the summation of all measured
laque areas and normalized by adjusting for the median
umber of images analyzed in the entire cohort to account
or heterogeneity of segment length:
TAVNormalized
 (EEMareaLumenarea)
Number of images in pullback
Median number of images in cohort
ercent atheroma volume (PAV) was calculated as the
ercentage of vessel wall occupied by atherosclerotic plaque:
PAV
 (EEMareaLumenarea)
EEMarea
100
tatistical analysis. Clinical characteristics and baseline
edication use were expressed as mean  SD for continu-
us variables and percentage for categorical variables. The
hi-square test or Fisher exact test were used, where
ppropriate, for categorical variables, and t tests were used
or continuous variables. Biochemical parameters with a
on-normal distribution (triglycerides, triglyceride/HDL
atio, apolipoprotein [apo]B, apoA-I, apoB/apoA-I ratio,
nd C-reactive protein [CRP]) were summarized using
edian and interquartile range. Absolute and percentage
hange for biochemical parameters and atheroma burden
ere summarized by treatment group, and the percentage
hange from baseline was tested within each treatment
roup and between treatment groups using an analysis of
ovariance model to adjust for the baseline value. For
nalysis purposes, biochemical parameters with a non-
ormal distribution were log-transformed. Percentage
hange from baseline was calculated as: log (follow-up
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January 11, 2011:153–9 Diabetes, Lipids, and Plaque Progressionalue/baseline value). The relationship between either base-
ine levels or changes in biochemical parameters and
hanges in PAV in the entire cohort were characterized by
orrelation coefficients. Substantial regression or progres-
ion was defined as 5% relative decrease or increase in
AV, respectively. Factors independently associated with
isease progression in the entire study cohort, and patients
reated with either pioglitazone or glimepiride, were deter-
ined by multivariable linear regression analysis. In addi-
ion to baseline characteristics (age, sex, race, body mass
ndex, smoking status, and self-reported history of hyper-
ension, hypercholesterolemia, myocardial infarction, coro-
ary intervention, and concomitant medication use), bio-
hemical parameters considered for inclusion in the model
ncluded change in glycated hemoglobin (HbA1c), LDL-C,
DL-C, triglycerides, triglycerides/HDL-C ratio, apoB,
poA-I, apoB/A-I ratio, and CRP. Baseline percent ather-
ma volume was forced into the model, and variables with
p value 0.15 were retained. All statistical analyses were
erformed using SAS version 9.1 (SAS Institute, Cary,
orth Carolina).
esults
atient characteristics. The clinical characteristics and
oncomitant medication use of patients are summarized in
able 1. Patients had a mean age of 60 years, were
redominantly male, and had a high prevalence of obesity.
ioglitazone-treated patients were less likely to be current
linical Characteristicsnd Concomitant Medication UseTable 1 Cli ical Characteri ticsand Concomitant Medication Use
Parameter
Glimepiride
(n  181)
Pioglitazone
(n  179) p Value
Age, yrs 60.0 8.8 59.6 8.8 0.65
Male 65.7 73.2 0.13
Body mass index, kg/m2 32.2 5.3 31.9 5.1 0.57
Current smoker 19.3 10.1 0.01
Hypertension 90.6 84.9 0.01
Hypercholesterolemia 92.3 89.9 0.44
Previous MI 24.9 33.0 0.09
Previous PCI 37.0 41.9 0.34
Previous CABG 1.1 1.7 0.68
Concomitant medication use
Statin 87.3 91.1 0.25
High-dose statin 34.2 31.7 0.91
Beta-blocker 80.1 77.7 0.57
ACE/ARB 87.8 88.8 0.77
Metformin 68.0 68.2 0.97
Insulin 22.7 17.9 0.26
alues are mean  SD or %. Clinical characteristics and concomitant medication use in patients
reated with glimepiride or pioglitazone.
ACE  angiotensin-converting enzyme; ARB  angiotensin-receptor blocker; CABG  coronary
rtery bypass graft surgery; MImyocardial infarction; PCI percutaneous coronary intervention. B
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Diabetes, Lipids, and Plaque Progression January 11, 2011:153–9mokers and were slightly less likely to have a history of
ypertension. No differences were noted between groups
ith regard to concomitant medication use. In particular,
here was no difference in the background use of statin
herapy, regardless of dose.
iochemical parameters and measures of atheroma burden.
evels of biochemical parameters and measures of atheroma
urden at baseline and the serial change in these parameters
re summarized in Table 2. Pioglitazone-treated patients
emonstrated slightly greater reductions in HbA1c (0.6
.01% vs. 0.4  0.1%, p  0.01) and greater relative
eductions in triglycerides (15.3  2.8% vs. 0.6  2.7%,
 0.001), triglyceride/HDL-C ratio (26.4  3.5% vs.
2.6  3.3%, p  0.001), apoB (5.0  1.7% vs. 1.7 
.6%, p  0.003), apoB/A-I ratio (11.0  2.0% vs. 4.2
1.8 %, p  0.005), and CRP (44.9  7.6% vs. 18.0
7.3%, p  0.001). A greater relative increase in HDL-C
16.1  1.4% vs. 4.2  1.3%, p  0.001) was also observed
ith pioglitazone, despite no differential effect on apoA-I.
ioglitazone had a favorable effect on progression of PAV
0.16  0.21% vs. 0.73  0.20%, p  0.002) and TAV
5.5 1.6 mm3 vs.1.5 1.5 mm3, p 0.06) compared
ith glimepiride.
elationship between biochemical parameters and change
n atheroma burden. The relationship between changes in
iochemical parameters and changes in measures of ather-
ma burden are summarized in Table 3. Significant univar-
ate correlations were observed between changes in PAV
nd changes in triglycerides, the triglyceride/HDL-C ratio,
nd HbA1c in pioglitazone-treated patients and changes in
DL-C, apoB, and apoA-I in glimepiride-treated patients.
ignificant correlations were also observed between changes in
AV and changes in HDL-C, triglyceride/HDL-C, and
bA1c with pioglitazone and changes in apoA-I with
limepiride. For the entire cohort, changes in biochemical
arameters in patients who underwent a substantial degree of
laque regression (n  59, 5% relative decrease in PAV) or
elationship Between Percentage Change in Biochemical Paramethange in Percent Atheroma Volume by Treatment GroupTable 3 Relations ip B tween Percentage Change in BiochemiChange in Percent Atheroma Volume by Treatment Gro
Parameter
Percent Atheroma Volume
Glimepiride Pioglita
r Value p Value r Value
LDL-C 0.15 0.05 0.03
HDL-C 0.06 0.42 0.08
Triglyceride* 0.01 0.85 0.15
Triglyceride/HDL-C* 0.02 0.83 0.16
ApoB* 0.16 0.04 0.09
ApoA-I* 0.20 0.01 0.08
ApoB/A-I* 0.03 0.65 0.13
HbA1c 0.17 0.02 0.16
CRP* 0.02 0.79 0.07
Body weight 0.07 0.34 0.5
artial correlation coefficients for the relationship between changes in biochemical parameters an
sed for variables with nonnormal distribution.
Abbreviations as in Tables 1 and 2.rogression (n 76,5% relative increase in PAV) were also
nvestigated. Substantial regression, compared to progression,
as associated with a greater relative increase in HDL-C
14.2 2.4% vs. 7.8 2.1%, p 0.04), relative reductions in
riglyceride (13.3 4.7% vs.1.9 4.1%, p 0.045), and
riglyceride/HDL-C ratio (22.5  5.9% vs. 9.9  5.2%,
 0.05), and decrease in HbA1c (0.6  0.1% vs. 0.3 
.1%, p  0.01). The relationship between changes in bio-
hemical parameters and measures of atheroma burden in the
reatment groups was explored further by examination of
ertiles of changes in these parameters. Significant univariate
elationships were noted between decreasing levels of the
riglyceride/HDL-C ratio and HbA1c with slowing of PAV in
ioglitazone-treated patients. In contrast, there was no signif-
cant association between changes in biochemical parameters
nd PAV in patients treated with glimepiride (Table 4).
imilarly, greater decreases in the triglyceride/HDL-C ratio
nd HbA1c were associated with slower rates of progression of
AV, although the latter just failed to meet statistical signif-
cance (Table 5).
On multivariable analysis of pioglitazone-treated pa-
ients, factors that were independently associated with
rogression of PAV included the change in the
riglyceride/HDL-C in the pioglitazone-treated patients
p  0.03). In contrast, changes in these metabolic
arameters did not predict changes in PAV in glimepiride-
reated patients (Table 6). Similarly, baseline disease burden
p  0.001) and changing the triglyceride/HDL-C ratio
p  0.02), but not HbA1c (p  0.16) was independently
ssociated with changes in TAV in pioglitazone-treated
atients, whereas changes in these parameters were not
ssociated with changes in TAV in the glimepiride group.
n the adjusted model, the p value for the interaction term
etween treatment group and change in triglyceride/
DL-C ratio and change in PAV did not meet statistical
ignificance (p  0.14).
ndarameters and
Total Atheroma Volume
Glimepiride Pioglitazone
Value r Value p Value r Value p Value
0.65 0.11 0.15 0.01 0.94
0.28 0.01 0.93 0.15 0.05
0.04 0.07 0.33 0.14 0.07
0.03 0.08 0.29 0.16 0.03
0.23 0.12 0.10 0.07 0.37
0.31 0.16 0.04 0.04 0.58
0.10 0.03 0.68 0.09 0.25
0.03 0.09 0.21 0.15 0.04
0.34 0.11 0.16 0.11 0.14
0.48 0.05 0.47 0.04 0.61
ures of atheroma burden in patients stratified according to treatment group. *Log-transformationers acal P
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he optimal therapeutic approach towards reduction of car-
iovascular risk in patients with diabetes and established
oronary heart disease continues to be a source of considerable
ebate. In the current post hoc analysis of diabetic patients
ith coronary artery disease, changing levels of both the
riglyceride/HDL-C ratio and HbA1c were each associated
ith reduction in disease progression. However, multivariable
nalysis revealed that lowering the triglyceride/HDL-C ratio
as the only parameter independently associated with slowing
f disease progression with pioglitazone. This observation
ighlights the potential importance of atherogenic dyslipide-
ia as a therapeutic target to reduce cardiovascular risk in
atients with diabetes.
The association between changes in the triglyceride/
DL-C ratio and atheroma progression provides further
vidence of the role of abnormal lipid homeostasis in the
ropagation of diabetic cardiovascular disease. Atherogenic
yslipidemia, characterized by hypertriglyceridemia, low levels
hange in Percent Atheroma Burden by Tertile of Change in BiocheTable 4 Change in Percent Atheroma Burden by Tertile of Chan
Parameter Glimepiride
LDL-C T1 (8) T2 (8 to 13) T3 (13)
0.7 0.3 0.8 0.3 0.6 0.3
HDL-C T1 (1) T2 (1 to 17) T3 (17)
0.9 0.3 0.6 0.3 0.2 0.3
Triglyceride T1 (22) T2 (22 to 8) T3 (8)
0.9 0.4 0.6 0.3 0.6 0.3
Triglyceride/HDL-C T1 (30) T2 (30 to 6) T3 (6)
0.5 0.4 0.9 0.4 0.6 0.3
HbA1c T1 (10) T2 (10 to1.5) T3 (1.5)
0.4 0.4 0.4 0.4 1.1 0.3
CRP T1 (45) T2 (45 to 0) T3 (0)
0.3 0.4 0.6 0.4 0.9 0.3
Body weight T1 (0) T2 (02.8) T2 (2.8)
0.8 0.3 0.8 0.3 0.4 0.4
 tertile; other abbreviations as in Tables 2 and 3.
hange in Total Atheroma Burden by Tertile of Change in BiochemTable 5 Change in Total Atheroma Burden by Tertile of Change
Parameter Glimepiride
LDL-C T1 (8) T2 (8 to 13) T3 (13)
0.7 2.9 3.4 2.9 3.7 2.9
HDL-C T1 (1) T2 (1 to 17) T3 (17)
0.3 2.5 3.8 2.9 7.1 4.2
Triglyceride T1 (22) T2 (22 to 8) T3 (8)
0.9 3.5 0.5 2.9 4.3 2.6
Triglyceride/HDL-C T1 (30) T2 (30 to 6) T3 (6)
1.3 3.8 0.3 3.0 4.3 2.4
HbA1c T1(10) T2 (10 to1.5) T3 (1.5)
4.8 3.1 2.5 3.2 0.02 2.6
CRP T1 (45) T2 (45 to 0) T3 (0)
7.7 3.3 1.0 3.0 0.3 2.6
Body weight T1 (0) T2 (0 to 2.8) T2 (2.8)
2.4 2.8 0.05 2.8 4.7 3.3bbreviations as in Tables 2, 3, and 4.f HDL-C, and normal levels of LDL-C, is commonly
ncountered in patients with diabetes (19). The influence of
hese lipid abnormalities on the arterial wall may explain the
bserved benefit with pioglitazone treatment. This drug has
avorable effects on triglycerides and HDL-C, but minimal
ffects on levels of LDL-C. These findings are consistent with
prior report that raising HDL-C predicted slowing progres-
ion of carotid intimal-medial thickness with pioglitazone in
iabetic patients (20). While the lack of a similar association in
atients treated with glimepiride is likely to reflect their lack of
ffect on triglycerides and HDL-C, it remains to be deter-
ined whether there are other factors underlying the differ-
nces between the agents.
The finding that LDL-C is not a predictor of disease
rogression in the current analysis of pioglitazone-treated
atients, most of whom were treated with a statin at
aseline, is likely to reflect the relative importance of
therogenic dyslipidemia in diabetes and does not detract
rom reports that LDL-C is independently associated with
l ParameterBiochemical Parameter
alue Pioglitazone p Value
.77 T1 (8) T2 (8 to 13) T3 (13) 0.44
0.1 0.3 0.5 0.3 0.3 0.4
.29 T1 (1) T2 (1 to 17) T3 (17) 0.26
0.3 0.5 0.05 0.4 0.3 0.3
.72 T1 (22) T2 (22 to 8) T3 (8) 0.52
0.5 0.3 0.1 0.4 0.2 0.4
.99 T1 (30) T2 (30 to 6) T3 (6) 0.05
0.5 0.3 0.1 0.4 0.6 0.5
.12 T1 (10) T2 (10 to1.5) T3 (1.5) 0.01
0.8 0.3 0.05 0.3 0.7 0.4
.25 T1 (45) T2 (45 to 0) T3 (0) 0.70
0.2 0.3 0.1 0.4 0.02 0.5
.47 T1 (0) T2 (0 to 2.8) T3 (2.8) 0.14
0.4 0.4 0.4 0.4 0.4 0.3
arameteriochemical Parameter
alue Pioglitazone p Value
.30 T1 (8) T2 (8 to 13) T3 (13) 0.90
5.5 2.5 8.7 2.5 5.9 2.6
.13 T1 (1) T2 (1 to 17) T3 (17) 0.12
1.2 3.3 7.9 2.6 8.2 2.1
.37 T1 (22) T2 (22 to 8) T3 (8) 0.16
8.7 2.3 7.2 2.6 2.8 3.1
.41 T1 (30) T2 (30 to 6) T3 (6) 0.05
8.8 2.1 7.9 2.5 0.2 3.4
.25 T1 (10) T2 (10 to1.5) T3 (1.5) 0.07
10.2 2.4 5.7 2.4 3.1 3.0
.11 T1 (45) T2 (45 to 0) T3 (0) 0.21
9.1 2.3 5.5 2.6 4.4 3.2
.66 T1 (0) T2 (0 to 2.8) T3 (2.8) 0.20
8.4 2.7 8.5 2.7 4.0 2.3micage in
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isease (21–23). Furthermore, the findings do not diminish
he importance of lowering LDL-C in diabetic patients
ith coronary artery disease.
The relationship between the degree of glycemic control
nd disease progression is controversial. The current find-
ngs support previous reports that HbA1c, a measure of
hronic glucose homeostasis, weakly correlates with the
egree of disease progression (17,24) and cardiovascular risk
25,26) in population-based studies. Although a statistically
ignificant difference was observed between glimepiride and
ioglitazone in effects on HbA1c, the absolute difference
as relatively small and unlikely accounted for the marked
enefit of pioglitazone in arresting disease progression.
The finding that changes in HbA1c were not indepen-
ently associated with disease progression, after controlling
or additional cardiovascular risk factors, is consistent with
ecent reports demonstrating no benefit of intensive glucose
owering on macrovascular outcomes (6–9). Although a
ecent meta-analysis of glucose lowering trials suggested
ardiovascular benefit (27), this has yet to be demonstrated
n an appropriately powered randomized clinical trial. We
id observe a weak relationship between changes in mea-
ures of glycemic control and atheroma progression, but that
as predominantly driven by the finding of accelerated
isease progression in those subjects whose HbA1c in-
reased. These findings suggest that marked and sustained
owering of glucose might have a beneficial impact on
oronary atherosclerosis. The current findings do not ex-
lude the possibility that the benefit of pioglitazone was not
ue, in part, to a reduction in insulin resistance. This
elationship requires additional investigation in further
tudies. Accordingly, there remains considerable interest in
etermining whether antidiabetic therapies can have a
ardiovascular benefit.
tudy limitations. A number of caveats in the interpreta-
ion of the current study should be noted. All patients had
resented for a clinically indicated coronary angiogram. It
emains uncertain whether the current findings can be
xtrapolated to asymptomatic subjects. The data are derived
ultivariable Predictors of Changes in Measures of Atheroma BurdTable 6 Multivariable Predictors of Changes in Measures of At
Parameter
Glimepiride
Beta Standardized Estimate p Value Be
Percent atheroma volume
Baseline burden 0.03 0.10 0.21 0
Change triglyceride/HDL-C 0.008 0.007 0.93 0
Change HbA1c 0.31 0.14 0.18 0
Total atheroma volume
Baseline burden 0.03 0.15 0.07 0
Change triglyceride/HDL-C 0.52 0.06 0.50 1
Change HbA1c 1.38 0.08 0.46 3
redictors of changes in measures of atheroma burden in glimepiride- and pioglitazone-treat
ypercholesterolemia, metformin use, baseline HbA1c, baseline LDL, and baseline apoA-I.
Abbreviations as in Tables 2, 3, 4, and 5.rom study of a relatively small number of patients who were
nollowed up for only 18 months. It remains to be deter-
ined to what degree these associations persist on longer
ollow-up. Conventional gray scale ultrasonography has
imited resolution and cannot characterize atheroma mor-
hology. Accordingly, it remains uncertain whether changes
n measures of atherogenic dyslipidemia and glycemic con-
rol can result in changes in plaque composition. Traditional
ipid parameters were evaluated in the PERISCOPE study.
hanges in lipid subspecies may have contributed to these
esults, and this possibility will require further investigation
n future clinical trials of peroxisome proliferator activated
eceptor- agonists. Finally, although increasing data sup-
ort a relationship between disease progression and clinical
utcome (28), that requires ongoing validation. It remains
o be determined how the current findings can be applied to
ssessment of the risk of adverse cardiovascular outcomes.
onclusions
n summary, a favorable effect on the triglyceride/HDL-C
atio was independently associated with slowing of progres-
ion of coronary atherosclerosis in patients with diabetes
nd established coronary artery disease. This finding sup-
orts the hypothesis that pioglitazone halted disease pro-
ression predominantly because of its properties beyond
lycemic control. These findings are also consistent with
linical outcome data indicating the importance of athero-
enic dyslipidemia as a target for therapeutic manipulation
n patients with diabetes mellitus to achieve more effective
revention of cardiovascular disease.
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